GPCM
ADMS

Granite Point Capital Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Granite Point Capital Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-54,822
Closed -$340K – 99
2019
Q2 		$340K Hold
54,822
– – 0.02% 83
2019
Q1 		$390K Hold
54,822
– – 0.04% 93
2018
Q4 		$468K Sell
54,822
-139,893
-72% -$1.82M 0.09% 77
2018
Q3 		$3.9M Sell
194,715
-7,400
-4% -$174K 0.26% 37
2018
Q2 		$5.22M Sell
202,115
-40,800
-17% -$1.13M 0.47% 23
2018
Q1 		$5.81M Sell
242,915
-27,600
-10% -$870K 0.56% 13
2017
Q4 		$9.17M Sell
270,515
-63,000
-19% -$1.76M 0.9% 6
2017
Q3 		$7.06M Buy
333,515
+70,000
+27% +$1.28M 1.49% 8
2017
Q2 		$4.61M Buy
263,515
+28,000
+12% +$463K 1.14% 13
2017
Q1 		$4.12M Sell
235,515
-20,516
-8% -$350K 1.23% 9
2016
Q4 		$4.33M Buy
256,031
+31,700
+14% +$490K 3.45% 6
2016
Q3 		$3.68M Hold
224,331
– – 1.44% 17
2016
Q2 		$3.4M Buy
+224,331
New +$3.7M 1.46% 12
2015
Q4 		$2.85M Buy
100,631
+45,000
+81% +$758K 0.43% 12
2015
Q3 		$931K Sell
55,631
-6,182
-10% -$141K 0.64% 40
2015
Q2 		$1.62M Hold
61,813
– – 0.47% 30
2015
Q1 		$1.08M Hold
61,813
– – 0.39% 44
2014
Q4 		$1.07M Hold
61,813
– – 0.5% 40
2014
Q3 		$1.04M Buy
+61,813
New +$1.06M 0.52% 39

Other funds holding ADMS

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Granite Point Capital Management's ADMS Position: Q3 2019 in Review

Granite Point Capital Management sold out of Adamas Pharmaceuticals (ADMS) in Q3 2019, closing a stake of 54,822 shares — an estimated $340K sold.

Granite Point Capital Management first reported a position in ADMS in Q3 2014 and held it in 19 quarters. The position peaked at $9.17M in Q4 2017. 87 funds tracked by Wall St. Rank hold ADMS as of Q3 2019.

  • Granite Point Capital Management reported no remaining Adamas Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Granite Point Capital Management sold 54,822 Adamas Pharmaceuticals shares in Q3 2019, an estimated $340K.
  • Granite Point Capital Management first reported a position in Adamas Pharmaceuticals in Q3 2014 and held it in 19 quarters.
  • Granite Point Capital Management's Adamas Pharmaceuticals position peaked at $9.17M in Q4 2017.
  • 87 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2019.

Based on Granite Point Capital Management's 13F filing for Q3 2019, filed 30 Oct 2019.